Opthea

67 articles with Opthea

• Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

  12/12/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA.

• Opthea to Present at the FLORetina 2022 Congress

  12/6/2022

  Opthea Limited announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022.

• Opthea to Present at Jefferies 2022 London Healthcare Conference

  11/10/2022

  Opthea Limited announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT.

• 

  Movers & Shakers: Adaptive Phage, Atossa, Nimbus and more

  10/28/2022

  New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.

• Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer

  10/24/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Timothy E. Morris as Chief Financial Officer, effective 24 October 2022.

• Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights

  8/30/2022

  Opthea Limited reported financial results for the fiscal year ended June 30, 2022 and provided an overview of recent progress.

• Opthea Successfully Closes Well Supported US$90 Million Equity Financing

  8/15/2022

  Opthea Limited is pleased to confirm it has received binding commitments for a successful two-tranche placement of new fully paid ordinary shares to institutional investors to raise approximately US$90 million1 at a price of A$1.15 per New Share, which represents a 12.6% discount to the 10-day Volume-Weighted Average Price as of 10 August 2022.

• Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

  8/15/2022

  Opthea Limited announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration.

• Opthea To Present at Upcoming Investor Conferences - May 11, 2022

  5/11/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at upcoming investor conferences in May.

• Opthea Presentation at The Retina World Congress 2022

  5/10/2022

  Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces a presentation at the upcoming Retina World Congress 2022, taking place in Fort Lauderdale, Florida from May 12-15, 2022.

• Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

  5/5/2022

  Opthea Limited announced the clinical data was presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting.

• Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

  4/29/2022

  Opthea Limited announces the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology 2022 conference, taking place in Denver, CO from May 1-4, 2022 and virtually from May 11-12, 2022.

• Opthea strengthens its Board of DirectorsElects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of Shareholders

  4/22/2022

  Opthea Limited today announced the appointment of Mr. Quinton Oswald and Dr. Susan Orr to its Board of Directors, effective immediately following election at a General Meeting of Shareholders on April 21st , 2022.

• Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference

  3/10/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at Oppenheimer’s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022.

• Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer

  3/2/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Dr. Joel Naor as Chief Medical Officer, effective 1 March 2022.

• Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

  2/14/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.

• Opthea To Present at SVB Leerink Global Healthcare Conference

  2/10/2022

  Opthea Limited announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022.

• Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

  2/9/2022

  Opthea Limited announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022.

• Opthea Receives A$6.6 m R&D Tax Incentive

  1/24/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received a A$6.6 million research and development tax credit from the Australian Taxation Office.

• Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference

  1/4/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the H.C. Wainwright BIOCONNECT Conference, being held virtually from January 10-13, 2022.